SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
NovaRx Corporation Announces FDA Approval of Protocol Amendment to Special Protocol Assessment (SPA) for Phase III Lucanix(R) Study in Non-Small Cell Lung Cancer
Your Message